Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR

September 1, 2010 By Bio-Medicine.Org

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1
/PRNewswire-FirstCall/ — QRxPharma (ASX: QRX and OTCQX: QRXPY)
announced today a successful interim analysis of its final MoxDuo
IR pivotal Phase 3 study required for New Drug Application (NDA)
submission. The analysis indicated the planned sample size of 140
patients has greater than 90% power to detect differences of
analgesic effect, indicating there is no need to enrol additional
patients. QRxPharma anticipates completing analysis of this study
in Q4 CY2010 and filing a New Drug Application (NDA) for MoxDuo IR
in Q1 CY2011.

“It’s certainly exciting – as we near completion of our
MoxDuo IR clinical program – that interim analysis of the
final pivotal study indicates we’re on track to obtain significant
results,” said Dr. John Holaday, Managing Director and CEO. “In
study after study this product has performed consistently,
successfully achieving every primary end-point. Our emphasis has
been to de-risk the MoxDuo IR clinical development program, and
these data give us confidence that completion of this study will
achieve primary pain relief endpoints and satisfy requirements for
NDA filing.”

QRxPharma is currently completing its product registration
clinical program for MoxDuo IR (a 3:2 ratio of morphine to
oxycodone) in the management of moderate to severe acute pain. This
comparative study conducted at 10 centres in the US, now well over
halfway complete, is evaluating analgesic efficacy and tolerability
of a flexible dose regimen (12 mg/8 mg) versus a fixed low dose (3
mg/2 mg) of MoxDuo IR in 140 patients with moderate to severe pain
following total knee replacement surgery.

The study design included a blinded interim analysis (70
completed patients) to be conducted by an independent statistician
for the purpose of sample size confirmation. This interim analysis
indicated that the projected sample size of 140 patients is likely
to provide sufficient power to distinguish the

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech